Bristol Myers Squibb (CELG-RI) Long-Term Investments (2009 - 2026)

Bristol Myers Squibb has disclosed Long-Term Investments across 17 years of filings, most recently posting $366.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 6.4% year-over-year to $366.0 million; the TTM figure through Mar 2026 stood at $366.0 million (up 6.4% YoY), while the FY2025 annual figure was $396.0 million, up 23.75% from the prior year.
• Long-Term Investments fell to $366.0 million in Q1 2026, from $396.0 million in the prior quarter.
• Over the last five years, Long-Term Investments for CELG-RI reached as high as $406.0 million in Q3 2025 and fell as low as $320.0 million in Q4 2024.
• The 4-year median for Long-Term Investments is $360.5 million (2023), against an average of $359.0 million.
• Annual changes were most pronounced in 2024 — Long-Term Investments decreased 12.09% — and 2025, when it increased 25.31%.
• A 4-year view of Long-Term Investments shows it stood at $364.0 million in 2023, then retreated by 12.09% to $320.0 million in 2024, then rose by 23.75% to $396.0 million in 2025, then slipped by 7.58% to $366.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $366.0 million, $396.0 million, and $406.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.